[go: up one dir, main page]

CR9426A - Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares - Google Patents

Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares

Info

Publication number
CR9426A
CR9426A CR9426A CR9426A CR9426A CR 9426 A CR9426 A CR 9426A CR 9426 A CR9426 A CR 9426A CR 9426 A CR9426 A CR 9426A CR 9426 A CR9426 A CR 9426A
Authority
CR
Costa Rica
Prior art keywords
agomelatine
treatment
obtaining
bipolar disorders
medicines
Prior art date
Application number
CR9426A
Other languages
English (en)
Inventor
Debodinat Christian
Mocaer Elisabeth
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9426(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR9426A publication Critical patent/CR9426A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invencion se refiere a la utilizacion de la agomelatina o N-(2-(7-metoxi-1-naftil) etil) acetamida sola o en asociacion para la obtencion de medicamentos destinados al tratamiento de los trastornos bipolares, principalmente de los trastornos bipolares de los tipos I y II, y mas particularmente de los trastornos bipolares de tipo I.
CR9426A 2005-04-20 2007-10-08 Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares CR9426A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Publications (1)

Publication Number Publication Date
CR9426A true CR9426A (es) 2008-02-21

Family

ID=35311309

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9426A CR9426A (es) 2005-04-20 2007-10-08 Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares

Country Status (40)

Country Link
US (1) US7947743B2 (es)
EP (1) EP1714647B1 (es)
JP (2) JP4580364B2 (es)
KR (2) KR100835451B1 (es)
CN (2) CN102038669A (es)
AP (1) AP2656A (es)
AR (1) AR057277A1 (es)
AT (1) ATE491443T1 (es)
AU (1) AU2006201655B2 (es)
BR (1) BRPI0601285A8 (es)
CA (1) CA2544136C (es)
CR (1) CR9426A (es)
CY (1) CY1111257T1 (es)
DE (1) DE602006018822D1 (es)
DK (1) DK1714647T3 (es)
EA (1) EA013462B1 (es)
ES (1) ES2357901T3 (es)
FR (1) FR2884714B1 (es)
GE (1) GEP20094651B (es)
GT (1) GT200600141A (es)
HR (1) HRP20110083T1 (es)
IL (1) IL186373A (es)
JO (1) JO2666B1 (es)
MA (1) MA28266A1 (es)
ME (1) ME01951B (es)
MY (1) MY143171A (es)
NO (1) NO336010B1 (es)
NZ (1) NZ546630A (es)
PE (1) PE20061337A1 (es)
PL (1) PL1714647T3 (es)
PT (1) PT1714647E (es)
RS (1) RS51659B (es)
SG (1) SG126868A1 (es)
SI (1) SI1714647T1 (es)
TN (1) TNSN07364A1 (es)
TW (2) TWI318115B (es)
UA (1) UA83681C2 (es)
UY (1) UY29470A1 (es)
WO (1) WO2006111653A1 (es)
ZA (1) ZA200603160B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
EP2150525A1 (en) 2007-05-01 2010-02-10 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
CN1250214C (zh) * 2001-02-27 2006-04-12 奥索-麦克尼尔药品公司 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality

Also Published As

Publication number Publication date
EA200600600A1 (ru) 2006-10-27
RS51659B (sr) 2011-10-31
GEP20094651B (en) 2009-03-25
CA2544136C (fr) 2012-02-21
AR057277A1 (es) 2007-11-28
UY29470A1 (es) 2006-05-31
AP2007004212A0 (en) 2007-10-31
CA2544136A1 (fr) 2006-10-20
US20060240127A1 (en) 2006-10-26
PE20061337A1 (es) 2007-01-27
ES2357901T3 (es) 2011-05-03
TWI318115B (en) 2009-12-11
IL186373A (en) 2012-06-28
BRPI0601285A8 (pt) 2021-03-30
IL186373A0 (en) 2008-08-07
ATE491443T1 (de) 2011-01-15
TNSN07364A1 (en) 2008-12-31
FR2884714A1 (fr) 2006-10-27
KR100835451B1 (ko) 2008-06-09
KR20060110803A (ko) 2006-10-25
BRPI0601285A (pt) 2006-12-19
AU2006201655B2 (en) 2009-04-23
JP5341037B2 (ja) 2013-11-13
PT1714647E (pt) 2011-01-14
ZA200603160B (en) 2007-06-27
CN102038669A (zh) 2011-05-04
US7947743B2 (en) 2011-05-24
GT200600141A (es) 2006-11-22
EA013462B1 (ru) 2010-04-30
PL1714647T3 (pl) 2011-05-31
SI1714647T1 (sl) 2011-03-31
NZ546630A (en) 2007-09-28
HRP20110083T1 (hr) 2011-03-31
KR20080028389A (ko) 2008-03-31
EP1714647A1 (fr) 2006-10-25
MY143171A (en) 2011-03-31
DE602006018822D1 (de) 2011-01-27
WO2006111653A1 (fr) 2006-10-26
FR2884714B1 (fr) 2011-05-06
CN1853619A (zh) 2006-11-01
DK1714647T3 (da) 2011-03-07
MA28266A1 (fr) 2006-11-01
JP2006316056A (ja) 2006-11-24
ME01951B (me) 2011-10-31
TW200940049A (en) 2009-10-01
AU2006201655A1 (en) 2006-11-09
JO2666B1 (en) 2012-06-17
JP4580364B2 (ja) 2010-11-10
CY1111257T1 (el) 2015-08-05
TW200716083A (en) 2007-05-01
EP1714647B1 (fr) 2010-12-15
HK1093906A1 (en) 2007-03-16
CN1853619B (zh) 2011-02-02
NO20061705L (no) 2006-10-23
UA83681C2 (uk) 2008-08-11
SG126868A1 (en) 2006-11-29
AP2656A (en) 2013-05-07
NO336010B1 (no) 2015-04-20
JP2010280699A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
CY1124111T1 (el) Παραγοντες ρυθμισης γλουταμικου στην αντιμετωπιση ψυχικων διαταραχων
UY30262A1 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
EA200601449A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения нарушений сна у пациента с депрессией
CR9426A (es) Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares
CL2007003009A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del dolor, ansiedad y depresion.
UY30704A1 (es) Utilizacion de la agomeletina para la obtencion de medicamentos destinados al tratamiento del sindrome de smith magenis
EA201201123A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения обсессивно-компульсивного расстройства (окр)
AR055107A1 (es) Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
CL2007002518A1 (es) Compuestos derivados de indol indano; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos afectivos, de dolor, de hiperactividad por deficit de atencion, depresion y ansiedad, entre otras enfermedades.
AR063895A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de la leucomalacia periventricular
CU20070070A7 (es) Composición farmacéutica de agomelatina
AR055418A1 (es) Nueva asociacion entre la agomelatina y un agente timoregulador y las composiciones farmaceuticas que la contienen

Legal Events

Date Code Title Description
FC Refusal